fogsprayhk
Elcatonin (CAS No. 60731-46-6) | Synthetic Analogue of Eel Calcitonin
Product Description
Elcatonin (CAS No. 60731-46-6), also known in the literature as Carbocalcitonin, is a synthetic peptide drug modeled after eel calcitonin, a naturally occurring hormone with potent effects on calcium and bone metabolism. Calcitonin itself is secreted by the parafollicular cells (C cells) of the thyroid gland in mammals and plays an important role in maintaining calcium homeostasis by reducing blood calcium levels and inhibiting bone resorption. Eel calcitonin, discovered for its exceptionally strong potency compared to mammalian calcitonin, served as the basis for the development of Elcatonin as a more stable and clinically useful analogue.
The rationale behind the design of Elcatonin was to retain the beneficial anti-resorptive effects of calcitonin while improving stability, half-life, and bioavailability. Natural calcitonin peptides are often limited by enzymatic degradation and relatively short activity durations. By modifying the molecular structure, Elcatonin achieves enhanced resistance to enzymatic breakdown, thereby making it a valuable tool in both research and therapeutic development settings.
Bone Mineral Density and Osteoporosis ResearchOne of the major research applications of Elcatonin lies in the study of bone metabolism and osteoporosis. Osteoporosis, characterized by reduced bone mineral density (BMD) and increased fragility, results from an imbalance between bone resorption by osteoclasts and bone formation by osteoblasts.
Elcatonin (CAS No. 60731-46-6) | Synthetic Analogue of Eel Calcitonin
Product Description
Elcatonin (CAS No. 60731-46-6), also known in the literature as Carbocalcitonin, is a synthetic peptide drug modeled after eel calcitonin, a naturally occurring hormone with potent effects on calcium and bone metabolism. Calcitonin itself is secreted by the parafollicular cells (C cells) of the thyroid gland in mammals and plays an important role in maintaining calcium homeostasis by reducing blood calcium levels and inhibiting bone resorption. Eel calcitonin, discovered for its exceptionally strong potency compared to mammalian calcitonin, served as the basis for the development of Elcatonin as a more stable and clinically useful analogue.
The rationale behind the design of Elcatonin was to retain the beneficial anti-resorptive effects of calcitonin while improving stability, half-life, and bioavailability. Natural calcitonin peptides are often limited by enzymatic degradation and relatively short activity durations. By modifying the molecular structure, Elcatonin achieves enhanced resistance to enzymatic breakdown, thereby making it a valuable tool in both research and therapeutic development settings.
Bone Mineral Density and Osteoporosis ResearchOne of the major research applications of Elcatonin lies in the study of bone metabolism and osteoporosis. Osteoporosis, characterized by reduced bone mineral density (BMD) and increased fragility, results from an imbalance between bone resorption by osteoclasts and bone formation by osteoblasts.